|C - Cardiovascular System|
|C10 - Lipid Modifying Agents|
The DDDs are based on the treatment of hypercholesterolemia.
|C10A - Lipid Modifying Agents, plain|
Combinations of different cholesterol and triglyceride reducers are classified at separate 5th levels using the corresponding 50-series. The following ranking according to the ATC codes is used: Substances classified in ATC-group C10AA take precedence over C10AB etc.
Pantethine, which is also used in the treatment of hyperlipidemi, is classified as a vitamin in A11HA.
|C10AX - Other Lipid Modifying Agents|
This group comprises all cholesterol and triglyceride reducers, which cannot be classified in the preceding groups.
Sulodexide is classified in B01AB.
The DDD for evolocumab is based on dosing every second week.
|C10AX13 - Evolocumab|
|10 mg||P|| |